Bioanalysis, a leading MEDLINE indexed journal for bioanalysts, has just published the 2017 White Papers resulting from the conclusions/consensus of the 11th WRIB meeting held earlier in the year, as well as the interactive Decennial Index of the White Papers in Bioanalysis: "A Decade of Recommendations (2007-2016)". The journal is published by Future Science Group.
Each year, the Workshop on Recent Issues in Bioanalysis (WRIB) gathers a wide range of industry opinion leaders and regulatory authorities working on bioanalysis, biomarkers and immunogenicity to discuss the most current topics of interest, and to provide potential solutions aiming to improve quality, increase regulatory compliance and achieve scientific excellence. These yearly discussions are the starting point for fruitful exchanges of knowledge, and extensive sharing of ideas among presenters, regulators and attendees, and are distilled into a series of relevant recommendations.
The resultant free-access White Papers summarizing these conclusions and consensus points from each WRIB, are published in Bioanalysis, providing the global bioanalytical community with key information and practical solutions on topics and issues addressed each year.
The 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in in April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations, and regulatory agencies worldwide. WRIB is a forum 'where regulators and industry convene' for working together in the field of bioanalysis, biomarkers, and immunogenicity to improve global health.
The resulting 2017 White Papers have now been published, in three parts, covering recommendations for:
- Part 1: LCMS: Small Molecules, Peptides and Small Molecule Biomarkers;
- Part 2: Hybrid LBA/LCMS Biotherapeutics, Biomarkers and Immunogenicity Assays and Regulatory Agencies' Inputs;
- Part 3: LBA: Immunogenicity, Biomarkers and PK Assays.
After a decade of publishing these conclusions and consensus, Bioanalysis recently published a free-access, interactive Decennial Index of the WRIB White Papers: "A Decade of Recommendations (2007-2016)". It aims to that act as a general index, organized by topic, to easily consult all these recommendations and their evolution over time.
"We are delighted to be publishing this year's WRIB White Papers in Bioanalysis, which continues a series of articles that over the past years have always been among our most well-read publications" stated Sankeetha Nadarajah & Hannah Makin, Editors of Bioanalysis. They continued "This year also marks a key milestone, with a decade of recommendations from WRIB meetings. We are therefore excited to be publishing a comprehensive Special Feature that provides a general index of the White Papers published to date, covering a variety of topics in bioanalysis and arranged in a clear and interactive manner, which we hope readers will find both informative and useful."
The White Papers and the Decennial Index can be found at the links below:
2017 WRIB White Paper 1: https:/
2017 WRIB White Paper 2: https:/
2017 WRIB White Paper 3: https:/
Decennial Index: https:/
Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 7,500 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews and commentaries. Membership is completely free of charge. Sign up online at: http://www.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. http://www.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.